| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO | President & CEO +3 more
4 companies
Edward M. Kaye MD is Director at STOK, with reported holdings spanning 4 companies. From February 2015 to October 2026, the filings on record show 1 open-market purchase and 30 sales. Edward M. Kaye MD's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.4M at current prices.
Our model assigns Edward M. Kaye MD a below-average insider score of 45/100, based on 26 past trades. Over a 12-month horizon, 16.7% of those trades were profitable, with an average 12-month return of -42.0%.
Edward M. Kaye MD's largest disclosed position is in STOK as Director, worth about $3.4M. The STOK filings lean toward selling, a net 320,351 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | CYTK Cytokinetics Inc | Director | Sell10b5-1 | 6,695 | $55.08 | $368,760.60 | -28.8% | +12.4% | +19.9% | |
| Sep 3, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sell10b5-1 | 61,885 | $20.13 | $1,245,697.68 | -40.3% | +50.8% | +51.7% | |
| Sep 2, 2025 | CYTK Cytokinetics Inc | Director | Sell10b5-1 | 6,756 | $50.00 | $337,800.00 | -22.5% | +33.1% | +45.0% | |
| Aug 18, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sell | 12,126 | $18.24 | $221,153.99 | -7.3% | +45.6% | +73.6% | |
| Jun 5, 2025 | CYTK Cytokinetics Inc | Director | Sell10b5-1 | 3,636 | $32.10 | $116,715.60 | -10.9% | +55.8% | +122.8% | |
| Mar 19, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sell | 19,289 | $8.49 | $163,672.83 | -12.2% | +41.2% | +301.8% | |
| Dec 9, 2024 | STOK Stoke Therapeutics, Inc. | CEO | Sell | 6,786 | $12.99 | $88,158.28 | -9.9% | -42.2% | +121.4% | |
| Dec 6, 2024 | STOK Stoke Therapeutics, Inc. | CEO | Sell | 6,170 | $12.78 | $78,837.18 | -8.2% | -38.6% | +132.6% | |
| May 20, 2024 | STOK Stoke Therapeutics, Inc. | CEO | Sell10b5-1 | 42,350 | $15.43 | $653,529.16 | -61.1% | -7.8% | -37.6% | |
| Mar 19, 2024 | STOK Stoke Therapeutics, Inc. | CEO | Sale+OE | 11,150 | $6.10 | $67,999.39 | -13.9% | +169.0% | +42.4% |